Faecalibacterium prausnitzii Depletion Linked to Lupus Progression in UT Health San Antonio Study Published in Nature Communications

The study published in Nature Communications profiled gut microbiomes from systemic lupus erythematosus patients and identified consistent reductions in F. prausnitzii relative to healthy controls. In established lupus-prone mouse strains, daily oral dosing with live F. prausnitzii partially restored regulatory T-cell populations, lowered anti-dsDNA antibody titers, and attenuated glomerulonephritis and splenomegaly. These effects occurred without measurable systemic immunosuppression, distinguishing the approach from corticosteroids or mycophenolate mofetil.

F. prausnitzii produces butyrate that supports colonic mucin integrity and shifts microbial metabolism away from mucin foraging. Prior observational work in NEJM and Cell Host & Microbe had already linked reduced butyrate producers to higher SLEDAI scores, yet no strain had been tested therapeutically until this report. The current data therefore extend correlative findings into a causal, interventional framework while highlighting formulation obstacles: the obligate anaerobe loses viability rapidly upon oxygen exposure, necessitating enteric-coated or lyophilized delivery systems.

Translation to patients will require pharmacokinetic studies to confirm colonization and butyrate output, followed by randomized controlled trials powered for clinical endpoints such as flare rate and steroid-sparing effect. Genetic and dietary covariates that modulate engraftment remain unexamined and could limit efficacy across ancestries disproportionately affected by lupus.

If phase-1 safety data are favorable, the pathway could accelerate microbiome-based adjuncts for other antibody-mediated autoimmune diseases sharing similar butyrate deficits.